• news.cision.com/
  • HC Andersen Capital/
  • HC Andersen Capital Events 9/6: Meet the management in Scandinavian Medical Solutions, ExpreS2ion Biotechnologies and InDex Pharmaceuticals

HC Andersen Capital Events 9/6: Meet the management in Scandinavian Medical Solutions, ExpreS2ion Biotechnologies and InDex Pharmaceuticals

Report this content

HC Andersen Capital is today hosting digital events where you can meet and ask questions directly to the top management. It is free for all to attend.

Scandinavian Medical Solutions - Sourcing: How does SMS provide equipment for resale?
As a trading company of high quality used imaging diagnostic equipment, Scandinavian Medical Solutions (SMS) relies on providing scanners and having a large warehouse that is attractive to the company's customers, including hospitals and clinics worldwide. “Sourcing” (purchasing) is therefore important for investors to understand, as a large part of the value creation takes place in the sourcing process, and this actually also sets limits to the growth opportunities.  

Tune in and hear how SMS manages to have the right items on the shelves at the right prices, how they balance the risk of not building up stocks that cannot be sold, and how the company works with technology to optimize purchasing comparring to competitors when we together with the top management dive deeper into the sourcing area. At the end of 2021, SMS won a historically large supply of 13 used MRI scanners via Siemens Healthineers. All scanners are located in hospitals in the Capital Region and are expected to ensure double-digit million turnover by 2023.  

Most recently, SMS was out with the half-year report for the financial period 2021/2022, where the company was out to maintain the revenue expectations for the full year of DKK 80-85 million and EBITDA in the range of DKK 12-14 million. Here it also appeared that SMS has expanded the existing inventory to approx. DKK 32 million at the end of March 2022 (from approx. DKK 16 million at the end of September 2021).


Thursday 9th of June 11:00 - 11:30 AM

Register here.

ExpreS2ion Biotechnologies - Presentation of the Q1 report
Watch our live event where CEO of ExpreS2ion Biotechnologies, Bent Frandsen, and the CFO, Keith Alexander present the Q1 financial results. During the event, it will be possible to ask questions.    

Besides the financial results for the quarter, the focus could be on the results of the capital raise carried out in the quarter and updates from the pipeline both on the breast cancer and the late-stage Covid-19 vaccine candidate.    

ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines. Currently, the company is developing vaccines against Covid-19, breast cancer and influenza.


Thursday 9th of June 13:00 - 13:30 PM

Register here.

InDex Pharmaceuticals - Commercial Strategy
Meet InDex Pharmaceuticals’ external advisor, Daniel Lundberg who is presenting the company’s go-to-market strategy in the US with the phase III product cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis.    

InDex Pharmaceuticals revealed its strategy for the US market in connection with their Capital Markets Day – on March 14th, 2022. The company expects to self-commercialize the product in the very important US market with the expected product launch in 2027.    

Daniel Lundberg has extensive experience in the pharmaceutical industry and the gastrointestinal (GI) market, with 13 product launches on his CV. 


Thursday 9th of June 15:00 - 15:30 PM

Register here.



Disclaimer: HC Andersen Capital receives payment from Scandinavian Medical Solutions, ExpreS2ion Biotechnologies and InDex Pharmaceuticals for a DigitalIR/Corporate Visibility agreement.
 

Mie Halse
Head of Digital and Events
mie@hcandersencapital.dk
+45 28746640
 

HC Andersen Capital digitializes the relation between listed companies and investors. We work long-term for companies that want more visibility in the market.  #DemocraticIR - HC Andersen Capital works to democratize access to the financial markets.

Subscribe